ANVS Annovis Bio, Inc.
Healthcare$2.06-7.62%ClosedMarket Cap: $40.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
19.87
P/S
0.00
EV/EBITDA
-0.72
DCF Value
$0.84
FCF Yield
-20580.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-318.1%
ROA
-251.9%
ROIC
-1199.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-18.0M | $-17.6M | $— | — |
| Q4 null | $0.00 | NaN% | $-9.7M | $-9.8M | $— | — |
| FY null | $0.00 | NaN% | $-29.7M | $-28.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-7.4M | $-7.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-6.3M | $-6.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-6.3M | $-5.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-6.7M | $-5.9M | $— | — |
| FY null | $0.00 | NaN% | $-26.7M | $-24.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-4.4M | $-12.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-7.8M | $-5.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-7.8M | $-1.1M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-10.4M | $-22.2M | $-2.33 | — |